The case for vaccine development in the strategy to eradicate river blindness (onchocerciasis) from Africa.

Abstract

Onchocerciasis or river blindness is a neglected parasitic disease causing severe dermatitis and visual impairment, predominantly in Africa. Historically, onchocerciasis control targeted vector breeding sites, but the current strategy relies on mass administration of a single drug, ivermectin. As programmatic goals shift from reducing public health impact to active elimination, sole reliance on ivermectin is threatened by contraindications in areas coendemic for loiasis, an inability to break transmission in some foci, and the emergence of drug resistance. Here, we argue that prophylactic and therapeutic vaccines would accelerate elimination efforts and safeguard the enormous strides made in onchocerciasis control. These vaccines could be based on one or more of three lead candidates identified by a newly formed transatlantic partnership, The Onchocerciasis Vaccine for Africa Initiative.

• Authors: Benjamin L Makepeace, Simon A Babayan, Sara Lustigman, David W Taylor
• Journal: Expert review of vaccines (Expert Rev Vaccines) Vol. 14 Issue 9 Pg. 1163-5 ( 2015) ISSN: 1744-8395 [Electronic] England
• PMID: 26091691 (Publication Type: Editorial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)

Chemical References

• Vaccines

Topics

• Disease Transmission, Infectious (prevention & control)
• Drug Discovery (trends)
• Humans
• Immunotherapy (methods)
• International Cooperation
• Onchocerciasis, Ocular (immunology, prevention & control, therapy)
• Vaccines (immunology, isolation & purification)